// App-Quantinova.ai

: Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs

Researchers

Presenter

  • Francesco Bonella

Principal Investigators

  • Toby M. Maher

  • Vincent Cottin

  • Claudia Valenzuela

  • Marlies Wijsenbeek

  • Florian Voss

  • Klaus B. Rohr

  • Susanne Stowasser

Medical Centers

  • Interstitial and Rare Lung Disease Unit, Ruhrlandklinik, University Hospital, University of Duisburg-Essen, Essen, Germany

  • National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom

  • National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France,

  • Hospital Universitario La Paz, Universidad Autonoma de Madrid, Madrid, Spain

  • Department of Respiratory Medicine, Erasmus University Hospital Rotterdam, Rotterdam, Netherlands,

  • Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim Am Rhein, Germany

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

Locations

  • Germany

  • United Kingdom

  • France

  • Spain

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Autoimmune (AI)

Disease

  • Idiopathic pulmonary fibrosis

  • Scleroderma

  • Pulmonary fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved